OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex

Patrick Jaynes, Prasanna Vasudevan Iyengar, Sarah Kit Leng Lui, Tuan Zea Tan, Natali Vasilevski, Sarah Christine Elizabeth Wright, Giuseppe Verdile, Anand D. Jeyasekharan, Pieter J.a. EichhornScientific 2020 · DOI

TL;DR

This paper identifies OTUD4, a deubiquitinating enzyme, as a key positive regulator of the TGF-β signaling pathway. OTUD4 enhances TGF-β signaling through a positive feedback loop by stabilizing the TGF-β receptor complex at the plasma membrane and inactivating the negative regulator SMURF2, offering new therapeutic targets for TGF-β-driven diseases.

What Problem Does This Paper Address?

The Transforming Growth Factor-β (TGF-β) pathway is a critical signaling cascade involved in numerous cellular processes, including development, differentiation, and tissue homeostasis. Dysregulation of this pathway is implicated in various diseases, particularly cancer. While ubiquitination is known to play a crucial role in controlling the amplitude and intensity of TGF-β signaling, the precise mechanisms and the specific enzymes involved, especially deubiquitinating enzymes (DUBs), remain incompletely understood. Specifically, how these DUBs fine-tune receptor activity and downstream signaling remains an open question. This paper aims to identify and characterize novel DUBs that regulate the TGF-β pathway, focusing on their mechanisms of action and their role in disease contexts.

Methods

The researchers employed a multi-pronged approach to investigate OTUD4's role in TGF-β signaling:

  • shRNA-mediated knockdown and overexpression: To assess the impact of OTUD4 on TGF-β pathway activity, they used short hairpin RNAs (shRNAs) to reduce OTUD4 levels and expressed wild-type and catalytically inactive mutants of OTUD4 to observe its effects.
  • Luciferase reporter assays: A CAGA-luciferase reporter system was used to quantify TGF-β-induced transcriptional activity, serving as a readout for pathway activation.
  • Western blotting and immunoprecipitation: These techniques were used to analyze protein levels, phosphorylation status (e.g., pSMAD2), ubiquitination patterns, and protein-protein interactions between OTUD4 and TGF-β receptor components.
  • Quantitative real-time PCR (qRT-PCR): This method was used to measure mRNA levels of OTUD4 and known TGF-β target genes.
  • Biotinylation and pulldown assays: These experiments were performed to assess the presence of TGF-β receptor I (TβRI) at the cell surface.
  • Confocal immunofluorescence microscopy: Used to visualize the localization of TβRI within cells.
  • TCGA pan-cancer dataset analysis: This bioinformatics approach was used to correlate OTUD4 expression with TGF-β pathway activation and epithelial-mesenchymal transition (EMT) signatures across various cancer types.

Datasets

  • TCGA pan-cancer dataset: This dataset, comprising gene expression data from 12,290 tumor samples across various cancer types, was used to analyze the correlation between OTUD4 mRNA expression and TGF-β pathway activation (using MSigdb v6.1 Hallmark TGFβ signature) and generic EMT signatures.

Key Insights and Ideas

  • OTUD4 as a positive feedback regulator: The discovery that OTUD4 is itself a transcriptional target of the TGF-β pathway, and that its expression is upregulated upon TGF-β stimulation, reveals a crucial positive feedback loop that amplifies TGF-β signaling.
  • Dual mechanism of action: OTUD4's ability to regulate TGF-β signaling through both catalytically dependent and independent mechanisms is a significant finding, suggesting complex regulatory roles beyond simple deubiquitination.
  • Plasma membrane stabilization of TβRI: OTUD4's role in promoting the presence of TβRI at the plasma membrane is a key insight, as this receptor is essential for initiating TGF-β signaling. This suggests OTUD4 may inhibit endocytosis or promote recycling of the receptor.
  • Inactivation of SMURF2: OTUD4's ability to inactivate SMURF2, a known negative regulator of TGF-β signaling, highlights its multi-node regulation of the pathway, further enhancing signaling.
  • Context-dependent ubiquitination: The paper suggests that OTUD4's regulation of TβRI ubiquitination is context-dependent, with different ubiquitin chain topologies (K29, K48, K63) playing roles in receptor localization and expression, particularly after receptor activation.
  • Biomarker potential: The strong correlation between OTUD4 expression and TGF-β pathway activity across numerous cancer types suggests OTUD4 could serve as a valuable biomarker for TGF-β pathway activity and potentially for therapeutic response.

Key Results

  • OTUD4 knockdown reduces TGF-β activity: Depletion of OTUD4 significantly decreased TGF-β-induced transcriptional activity (CAGA-luciferase reporter) and phosphorylation of SMAD2 (pSMAD2), a key downstream signaling molecule.
  • OTUD4 overexpression enhances TGF-β activity: Ectopic expression of wild-type OTUD4, but not its catalytically inactive mutants, enhanced TGF-β-induced luciferase activity and pSMAD2 levels.
  • OTUD4 interacts with TβRI and TβRII: Immunoprecipitation experiments confirmed that OTUD4 forms a complex with both TβRI and TβRII.
  • OTUD4 deubiquitinates TβRI and TβRII: OTUD4 reduced the ubiquitination levels of both TβRI and TβRII, although the catalytically inactive mutant also showed some effect, suggesting both catalytic and non-catalytic roles.
  • OTUD4 increases cell surface TβRI: Biotinylation assays showed that OTUD4, particularly in the presence of TGF-β ligand, increased the presence of TβRI at the plasma membrane.
  • OTUD4 stabilizes SMURF2: Overexpression of OTUD4, including its catalytically inactive mutant, led to increased SMURF2 protein levels, suggesting OTUD4 negatively regulates SMURF2's auto-regulation and stability.
  • Correlation with cancer datasets: OTUD4 expression significantly correlated with TGF-β pathway activation in 25 out of 37 tumor types and with EMT signatures in 12 out of 37 tumor types, with positive correlations being more prevalent.

Limitations and Future Work

  • Non-catalytic functions: While the paper demonstrates OTUD4's non-catalytic functions in regulating SMURF2 and TβRI stabilization, the precise molecular mechanisms underlying these roles remain to be fully elucidated.
  • Ubiquitin chain specificity: While the study identified specific ubiquitin chain types (K29, K48, K63) involved in OTUD4's regulation of activated TβRI, further investigation is needed to fully understand how OTUD4's deubiquitinase activity dictates these specific chain removal events.
  • Phosphorylation and compartment-specific activity: The role of OTUD4 phosphorylation by kinases like CK2 and its activity in different cellular compartments (plasma membrane vs. post-endocytosis) warrants further investigation.
  • USP9X interaction: The potential involvement of USP9X in OTUD4-mediated TβR deubiquitination and stabilization, as hinted at by previous literature, was not fully explored in this study.
  • Therapeutic implications: While OTUD4 is proposed as a biomarker, further research is needed to explore its direct therapeutic potential in targeting TGF-β-driven cancers.

The authors suggest that understanding OTUD4's multifaceted regulation of the TGF-β pathway, particularly its role in receptor trafficking and SMURF2 inactivation, is crucial for developing targeted therapies for diseases where this pathway is dysregulated.

Summary updated

Abstract

Systematic control of the transforming growth factor-β (TGFβ) pathway is essential to keep the amplitude and the intensity of downstream signalling at appropriate levels. Ubiquitination plays a crucial role in the general regulation of this pathway. Here we identify the deubiquitinating enzyme OTUD4 as a transcriptional target of the TGFβ pathway that functions through a positive feedback loop to enhance overall TGFβ activity. Interestingly we demonstrate that OTUD4 functions through both catalytically dependent and independent mechanisms to regulate TGFβ activity. Specifically, we find that OTUD4 enhances TGFβ signalling by promoting the membrane presence of TGFβ receptor I. Furthermore, we demonstrate that OTUD4 inactivates the TGFβ negative regulator SMURF2 suggesting that OTUD4 regulates multiple nodes of the TGFβ pathway to enhance TGFβ activity.
BibTeX
@inproceedings{jaynes2020otud,
  author = {Patrick Jaynes and Prasanna Vasudevan Iyengar and Sarah Kit Leng Lui and Tuan Zea Tan and Natali Vasilevski and Sarah Christine Elizabeth Wright and Giuseppe Verdile and Anand D. Jeyasekharan and Pieter J.A. Eichhorn},
  title = {{OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-72791-0},
}
Figure